Provided herein is a method for preparing a silver complex. The method includes reacting a silver oxide with a mixture of ammonium carbamate and isopropyl amine at room temperature in the presence of methanol.

Provided herein is a method for preparing a silver complex. The method includes reacting a silver oxide with a mixture of ammonium carbamate and isopropyl amine at room temperature in the presence of methanol.

A method for producing metal carbonate is disclosed. The method includes the following steps of providing a first mixture of metal and a catalyst containing iron, NO groups, and N-containing ligands first; then introducing carbon dioxide to the first mixture to form a second mixture and obtaining a product. The method described here can improve the yield and decrease the cost of metal carbonate production.

A method for producing metal carbonate is disclosed. The method includes the following steps of providing a first mixture of metal and a catalyst containing iron, NO groups, and N-containing ligands first; then introducing carbon dioxide to the first mixture to form a second mixture and obtaining a product. The method described here can improve the yield and decrease the cost of metal carbonate production.

Compounds of formula (I) or a pharmaceutically acceptable ester, amide, carbamate or salt thereof, including a salt of such an ester, amide or carbamate in which R.sup.1 to R.sup.9 have meanings as defined in the Specification, are useful as estrogen receptor ligands.

##STR00001##

Compounds of formula (I) or a pharmaceutically acceptable ester, amide, carbamate or salt thereof, including a salt of such an ester, amide or carbamate in which R.sup.1 to R.sup.9 have meanings as defined in the Specification, are useful as estrogen receptor ligands.

##STR00001##

The invention provides a composition containing hyaluronic acid (HA) or a pharmaceutically-acceptable salt thereof preserved with a cationic preservative and related methods. In one embodiment, the pharmaceutically-acceptable salt is sodium hyaluronate. In another embodiment, the cationic preservative includes benzalkonium chloride (BAK).

Compounds of formula (I) or a pharmaceutically acceptable ester, amide, carbamate or salt thereof, including a salt of such an ester, amide or carbamate in which R.sup.1 to R.sup.9 have meanings as defined in the Specification, are useful as estrogen receptor ligands. ##STR00001##

Compounds of formula (I) or a pharmaceutically acceptable ester, amide, carbamate or salt thereof, including a salt of such an ester, amide or carbamate in which R.sup.1 to R.sup.9 have meanings as defined in the Specification, are useful as estrogen receptor ligands. ##STR00001##

The invention provides a composition containing hyaluronic acid (HA) or a pharmaceutically-acceptable salt thereof preserved with a cationic preservative and related methods. In one embodiment, the pharmaceutically-acceptable salt is sodium hyaluronate. In another embodiment, the cationic preservative includes benzalkonium.